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The evolutionary conserved protein Cdc48/VCP is involved in various cellular processes, such as protein degradation, membrane fusion and
chaperone activity. Increased levels of Cdc48/VCP correlate with cancer, whereas Cdc48/VCP at endogenous levels has been proposed to be a
pathological effector in protein deposition diseases. Upon mutation Cdc48/VCP triggers the multisystem disorder ‘inclusion body myopathy
associated with Paget's disease of bone and frontotemporal dementia’ (IBMPFD). The roles of Cdc48/VCP under these diverse pathological
conditions, especially its function in decreased and increased incidences of cell death underlying these diseases, are poorly understood. Mutation of
yeast CDC48 (cdc48S565G) results in yeast cells demonstrating morphological markers of apoptotic cell death. In other species it has been confirmed
that mutations and depletion of Cdc48/VCP cause apoptosis, whereas increased levels of this protein provide an anti-apoptotic effect. This review
critically compares mechanisms of Cdc48/VCP-mediated apoptosis observed in yeast and other species. Cdc48/VCP plays a triple role in cell death.
At first, loss-of-function of Cdc48/VCP due to mutation or depletion causes ER stress and oxidative stress, triggering apoptosis. Secondly, upon
exogenously applied ER stress functional Cdc48/VCP is important in the processing of caspases and plays therewith a pro-apoptotic role. Finally,
Cdc48/VCP protects cells from apoptosis through mediating and activating pro-survival signaling pathways, namely Akt and NFκB signaling. This
complex role in cell death pathways could correspond with the various pathophysiological conditions Cdc48/VCP is involved in.
© 2008 Elsevier B.V. All rights reserved.Keywords: CDC48; VCP; p97; Mitochondria; Oxidative stress; ER stress; Apoptosis; Cell survival1. Introduction
The yeast cell division cycle protein 48 (Cdc48p) and its
highly conserved mammalian orthologue valosin-containing
protein (VCP/p97) are ubiquitously expressed members of the
AAA-ATPase family (ATPases associated with various cellular
activities) [1–4]. Cdc48/VCP is made up of four domains: the
N-terminal domain, the ATPase domains D1 and D2, and the
C-terminal domain [5] (Fig. 1). The N-terminal domain binds
to cofactors, such as Ufd1 (ubiquitin-fusion degradation pro-
tein 1) and p47 [6], and to ubiquitinated substrates [5,7]. The⁎ Corresponding author. Current address: University of Graz, Institute of
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doi:10.1016/j.bbamcr.2008.01.015D1 domain mediates the oligomerization of Cdc48/VCP [5,8],
and the major ATPase activity of Cdc48/VCP has been as-
signed to the D2 domain [5,8]. The C-terminal domain of
Cdc48/VCP binds cofactors, such as the multiubiquitination
enzyme Ufd2 [9,10], and is involved in the phosphorylation-
dependent nuclear localization of yeast Cdc48p [11].
Similar to other AAA-ATPases, Cdc48/VCP assembles into
a stable homohexameric barrel structure with a small central
channel [12–16]. The homohexamer undergoes drastic confor-
mational changes during its nucleotide hydrolysis cycle pre-
sumably generating the mechanical force to dissociate large
protein complexes [15,17–19]. Cdc48/VCP specifically re-
moves ubiquitinated protein substrates from protein complexes
or other cellular structures, such as the ER membrane [7].
Applying this general paradigm, Cdc48/VCP is crucially in-
volved in several cellular functions controlled by ubiquitination
[7]. It is engaged in the proteasomal degradation of proteins, in
Fig. 1. Domain structure of Cdc48/VCP. Cdc48/VCP consists of the conserved N-terminal domain (N), two conserved AAA-ATPase domains (D1 and D2), and the
C-terminal domain (C). The numbers refer to the amino acid positions within the protein in yeast Cdc48p and human VCP, respectively.
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ER-associated degradation pathway (ERAD), in membrane
fusion, in transcriptional and cell cycle control, in chaperone-
like processing of protein aggregates, and in DNA repair (for
reviews: [5,7,20–25]).
Mutations in human VCP trigger the human multisystem
disorder ‘inclusion body myopathy associated with Paget's dis-
ease of bone and frontotemporal dementia’ (IBMPFD) [26–35].
This disorder is characterized by inclusion bodies in muscle or
brain [31,34,35]. Most patients suffer from a strongmyopathy that
may be associated with bone disease and/or frontotemporal
dementia [31,34]. Wild-type VCP co-localizes with protein
depositions characteristic for various neurodegenerative disorders,
such as polyglutamine, Parkinson's and Alzheimer's diseases
[36–38]. Therefore, VCP has been proposed to be a sensor for
aggregated proteins causative for these disorders [37,39]. In a
Caenorhabditis elegans model for polyglutamine diseases
Cdc48/VCP has been shown to disintegrate protein depositions
formed by proteins with expanded polyglutamine stretches [40],
and inmammalian cells VCP is involved in both the formation and
clearance of aberrant protein depositions [39,41]. In contrast,
elevated levels of VCP correlate with increased incidences of
metastasis in various types of cancer [42–55]. The underlying pro-
survival effect of elevated VCP levels and the role of Cdc48/VCP
in pathophysiological conditions associated with increased
incidences of cell death promoted the analysis of molecular
details of Cdc48/VCP in cell survival and cell death pathways.
Expression of a mutant form of yeast Cdc48p (Cdc48p-
S565G) resulted in yeast cells demonstrating morphological
markers of apoptotic cell death, previously known only from
multicellular organisms [56]. This finding initiated the detailed
analysis of programmed cell death in yeast and established
yeast as an important model for apoptosis research (for review:
[57–65]). According to the events in yeast expressing mutated
CDC48 (cdc48S565G), mutation and depletion of Cdc48/VCP in
other species lead to cell death with apoptotic features [66–69].
Thus, apoptosis due to Cdc48/VCP dysfunction is evolutionary
highly conserved. This striking coincidence points to yeast as
a suitable model organism for the analysis of Cdc48/VCP-
mediated cellular processes with potential relevance for human
pathophysiological conditions.
This review aims at describing and comparing mechanisms
of Cdc48/VCP-mediated apoptosis in yeast and other species,
especially mammalian cells. Emphasis is laid on relating the
data of Cdc48/VCP-dependent cell death with respect to VCP-
mediated human disorders.2. Apoptotic mechanisms in yeast cells expressing mutated
CDC48 (cdc48S565G)
2.1. Morphological markers of apoptosis in yeast expressing a
specific mutation of CDC48 (cdc48S565G)
Cdc48pwas the first apoptotic mediator found in S. cerevisiae
[56]. Replacement of a conserved serine residue in the second
ATPase domain (D2) of yeast CDC48 (serine 565 to glycine,
S565G, see Fig. 1) resulted in yeast cells with increased sus-
ceptibility to undergo cell death [56,70]. Cell death could be
triggered very efficiently by heat shock (37 °C), growth to late
exponential or stationary phases, ageing and radiation [56,71,72].
The dying cells demonstrated morphological markers of apop-
tosis: (i) nuclear fragmentation, (ii) chromatin condensation
and fragmentation, (iii) DNA fragmentation, (iv) cytoplasmic
vacuolization, (v) abnormally shaped cells, and (vi) transloca-
tion of the phospholipid phosphatidylserine from the inner to the
outer leaflet of the plasma membrane [56]. Inhibition of protein
synthesis applying the specific ribosome inhibitor cyclohex-
imide prevented the emergence of these apoptotic features
[71]. Since gene expression and protein synthesis are neces-
sary for completing “programmed” cell death scenarios, these
data demonstrated that yeast cells expressing mutated CDC48
(cdc48S565G) undergo programmed cell death with typical mark-
ers of apoptosis.
Apoptotic features are not a general phenomenon for all
known CDC48 mutations but appear to be rather specific for the
cdc48S565G allele. OtherCDC48 alleles, such as the temperature-
sensitive allele cdc48-3ts that triggers cell cycle arrest upon
elevated temperatures, lack morphological markers of apoptotic
cell death [56,71]. Therefore, the cdc48S565G mutation might
affect a specific cellular function that triggers apoptosis. The
amino acid exchange is localized in the highly conserved D2
domain that is responsible for the major ATPase activity of
Cdc48p (see Fig. 1), indicating that ATPase-deficiency of
Cdc48p-S565G may be important for apoptotic cell death.
2.2. Crucial role of reactive oxygen species (ROS) and
mitochondria during cell death in cdc48 yeast
The analysis of the molecular mechanisms underlying apo-
ptotic cell death in yeast cells expressing mutated CDC48
(cdc48S565G) resulted in the finding that ROS are involved in
cell death [71]. Marked accumulation of ROS could be detected
in apoptotic yeast cells expressing mutated CDC48 by staining
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are oxidized by ROS to fluorescent rhodamine and ethidium,
respectively [71]. Depletion of ROS upon addition of radical
scavengers to the growth media or due to growth of yeast cells
in an oxygen-free environment inhibited the accumulation of
ROS and prevented cells to undergo apoptosis even under
stress conditions (e.g., heat shock) [71]. These data demonstrate
that ROS play a pivotal role and are not a by-product in
apoptotic cell death in cells expressing mutated CDC48
(cdc48S565G).
Both exogenously applied oxidative stress through treat-
ment with low doses of hydrogen peroxide and endogenously
produced ROS, e.g., upon heterologous expression of the
mammalian pro-apoptotic factor Bax or upon treatment with
the yeast mating-type pheromone, trigger apoptotic cell death
in yeast [71,73,74]. Cells exposed to acidic stress and ageing
yeast cells can be removed from the yeast population via
ROS-dependent apoptosis [75–78]. Thus, the crucial role of
ROS in cells expressing mutated CDC48 (cdc48S565G) is in
line with several apoptosis pathways in yeast (for review:
[57,58,61]).
Endogenously produced ROS in yeast may be of
cytoplasmic or mitochondrial origin [79,80]. Deregulated
peroxisomal enzymes or a misregulated ER-resident oxida-
tive protein folding machinery has been reported to result in
the cytoplasmic production of ROS [79,80]. A major burst
of cellular ROS results from the deregulation of the
respiratory chain in the inner mitochondrial membrane
[81]. Applying a differential plating assay, we could show
that yeast cells expressing mutated CDC48 (cdc48S565G)
grown under apoptotic conditions were unable to proliferate
on lactate as obligatory respiratory carbon source [82].
These data hint to a decreased respiratory capacity of these
cells and point to a deregulation of the respiratory chain.
The use of specific inhibitors of the cytochrome bc1
complex of the respiratory chain significantly reduced the
number of yeast cells accumulating ROS [82]. Thus,
deregulation of the respiratory chain is one major cause
for the emergence of ROS and therewith for apoptotic cell
death in cells expressing mutated CDC48 (cdc48S565G). A
crucial mitochondrial role in cell death was confirmed by
generating CDC48 ρ0 and cdc48S565G ρ0 strains [82]. In
these yeast strains mitochondrial DNA was depleted during
growth on media containing low amounts of ethidium
bromide, resulting in yeast cells lacking functional mito-
chondria [83]. Under apoptotic conditions, cdc48S565G ρ0
cells were unable to accumulate ROS [82]. As evidenced by
a survival plating assay, the cell viability of cdc48S565G ρ0
cells was increased when compared to cdc48S565G ρ+ cells
[82]. Thus, mitochondria play a detrimental role in CDC48-
mediated apoptosis in yeast through production of death-
causing ROS.
A pro-apoptotic role of mitochondria has been shown in
several studies dealing with programmed cell death in yeast
(for review: [61]). Ludovico and colleagues demonstrated that
loss of mitochondrial membrane potential upon treatment of
yeast cells with low doses of acetic acid was correlated withthe accumulation of ROS and apoptotic cell death [77]. A
causative role of mitochondria in cell death was further
established with cells lacking mitochondrial DNA (ρ0 strains)
or cells defective in an essential component of the
mitochondrial ATP synthase complex (ATP10) [77]. In both,
and in contrast to wild-type cells, acetic acid-triggered
apoptosis did not occur [77]. In another study dealing with
apoptotic cell death in yeast upon treatment with elevated
levels of yeast pheromone, a burst of ROS produced by the
mitochondrial cytochrome bc1 complex of the respiratory
chain was demonstrated, resulting in cell death [84]. These
authors further proposed a sequence of events that resulted in
mitochondria-mediated apoptotic cell death, where pheromone
treatment lead to elevated levels of cytosolic Ca2+ ions
[61,84]. These cations triggered an increase in the respiratory
rate and in the energy coupling within the respiratory chain.
The consequent hyperpolarization of mitochondria resulted in
the accumulation of mitochondrially produced ROS and in the
fragmentation of the mitochondrial network within the cell
concomitant to the depolarization of mitochondria [84].
Mitochondrial enlargement, which might be a result of such
a hyper- and depolarization of mitochondria, was also
observed in apoptotic yeast cells expressing mutated CDC48
(cdc48S565G) [82]. Therefore, increased respiratory rate and the
consequent hyperpolarization might also precede the accumu-
lation of death-causing ROS in apoptotic cdc48S565G cells.
However, how such cellular events result in yeast, like in
mammalian cells, in the permeabilization of the inner
mitochondrial membrane and in mitochondrial rupture is still
a matter of debate [61,85–89].
Beside the production of ROS, mitochondria play a more
complex role during apoptosis. Cells expressing mutated
CDC48 released cytochrome c into the cytosol and showed
emergence of caspase-like enzymatic activity [82]. Cyto-
chrome c mutant yeast strains demonstrated decreased
apoptosis under hyperosmotic stress conditions compared to
wild-type strains [90]. Disruption of cytochrome c resulted in
delayed cell death in yeast pheromone-induced apoptosis
without affecting ROS production [74,84]. This indicates that
cytochrome c may play a pivotal pro-apoptotic role during
execution of apoptosis [74,84] and could therefore be an
important factor during cell death triggered by CDC48
mutation (cdc48S565G). A differential proteomic analysis
applying two-dimensional gel electrophoresis (2-DE) revealed
32 significant protein spot alterations at the mitochondrial
proteome level in apoptotic cells expressing mutated CDC48
(cdc48S565G) [82]. Among the observed altered proteins are
further promising candidates for regulating CDC48-mediated
mitochondria-dependent apoptosis:
(i) Accumulation of the yeast orthologue of the human ‘trans-
lationally controlled tumor protein’ (TCTP) was demon-
strated in mitochondrial extracts of the cdc48S565G mutant
strain under apoptotic conditions. Human TCTP was
proposed to be a modulator of apoptotic cell death in
mammalian cells [91,92]. Yeast TCTP, like human TCTP, is
a microtubule-binding cytoplasmic protein [93,94]. Yeast
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stress or replicative ageing of yeast cells [93] that is known to
be associated with the accumulation of ROS [76]. Therefore,
this yeast protein was termed ‘microtubule and mitochondria
interacting protein 1′ (Mmi1p) [93]. Deletion of the MMI1
gene resulted in yeast cells with markedly increased
resistance to oxidative stress and increased lifespan of
individual yeast cells [93]. Thus, Mmi1p may play an
important role in oxidative stress-dependent apoptosis in
yeast. Enrichment of Mmi1p in mitochondrial extracts of
cdc48S565G cells, which accumulated ROS predominantly
produced by mitochondria, suggests a role of this protein in
mitochondria-mediated cell death in the cdc48S565G strain.
(ii) Depletion of mitochondrial cyclophilin C (Cpr3p) in
mitochondrial extracts of apoptotic cdc48S565G yeast cells
was found. Very recently, Cpr3p was identified in a genetic
screen for mediators of Cu-induced apoptotic cell death in
yeast [95]. Here, the deletion of Cpr3p abrogated Cu-induced
apoptosis but did not interfere with ROS production [95]. In
contrast, lack of Cpr3p had no effect on acetic acid-induced
apoptosis in yeast [88,89]. If the observed depletion of
Cpr3p in mitochondrial extracts of cdc48S565G cells is an
attempt of the cells to escape cell death or if Cpr3p depletion
is itself pro-apoptotic under these conditions remains for
further investigations. The mammalian homologue cy-
clophilin D is an important regulator of mitochondria-
mediated apoptosis in mammalian cells [96–98]. It is in-
volved in the opening of the inner mitochondrial membrane
[96]. Despite intensive efforts, the exact role of cyclophilin
D in these processes is poorly understood and remains
highly controversial [97,98]. Therefore, the detailed analy-
sis of the role of Cpr3p during yeast cell death is of high
interest for the elucidation of apoptotic mechanisms in both
yeast and mammalian cells.
(iii) Two components of the actin cytoskeleton were found to be
accumulated in mitochondrial extracts in cdc48S565G cells. A
connection between yeast apoptosis and actin dynamics has
been established [99,100]. These authors demonstrated that
decreased actin dynamics caused depolarization of the
mitochondrial membrane and an increase in ROS production
resulting in cell death. Thus, the observed mitochondrial
damage and ROS production in the cdc48S565G strain conco-
mitant to the accumulation of proteins of the actin cytoske-
leton in mitochondrial extracts hint to an altered dynamic of
the actin cytoskeleton in apoptotic cdc48S565G cells.
(iv) Elevated amounts of mitochondrial ribosomal subunits
were observed. A transcriptome analysis of apoptotic
cdc48S565G cells revealed upregulation of several compo-
nents of the mitochondrial protein translation machinery
[101]. These data therefore point to active protein alterations
in mitochondria during the cell death program.
Yeast cells expressing mutant CDC48 (cdc48S565G) demon-
strated emergence of caspase-like activity. Yeast caspase-1
(YCA1) is a molecular regulator within several apoptotic sce-
narios in yeast [75,102–104]. Disruption of YCA1 completely
abrogated hydrogen peroxide-induced apoptosis [102]. There-fore, the observed emergence of caspase-like enzymatic activity
in cdc48S565G cells hint to a role of YCA1 during the apoptotic
process.
In summary, a specific mutation in CDC48 (cdc48S565G)
results in yeast cells showing typical markers of apoptosis.
ROS play an essential role during cell death. Mitochondria are
pivotal for the progression of programmed cell death. They
produce the detrimental ROS, show mitochondrial enlargement
and loss of respiratory capacity, they release cytochrome c into
the cytosol, and demonstrate distinct alterations at the
proteome level. These altered proteins should be analyzed in
the future, in order to elucidate distinct molecular mechanisms
of ROS- and mitochondria-dependent apoptosis typically for
cells expressing mutated CDC48 (cdc48S565G) in comparison
to other known yeast apoptotic pathways.
2.3. Dysfunction of mutated CDC48 (cdc48S565G) affects
mitochondria by increased levels of polyubiquitination
Expression of mutated CDC48 (cdc48S565G) results in
yeast cells with increased susceptibility to undergo ROS- and
mitochondria-dependent apoptotic cell death. However, to
date no specific role of Cdc48p is known with respect to the
cellular balance of oxidative stress or mitochondrial function-
ality. Therefore, it remains puzzling why a specific mutation
in CDC48 affects mitochondria and triggers apoptosis.
Cdc48p and its mammalian orthologue VCP are involved in
many different cellular processes mostly controlled by
ubiquitination, such as protein degradation of ER proteins
(ERAD), cell cycle control and membrane fusion [20–25].
Apoptotic cdc48S565G cells do not arrest during cell cycle,
whereas yeast cells expressing CDC48 alleles resulting in cell
cycle arrest, such as cdc48-3ts, do not show typical markers
of apoptotic cell death [5,7,56]. Thus, the high susceptibility
to undergo apoptosis is probably not due to a dysfunction of
mutated CDC48 (cdc48S565G) in cell cycle control. In contrast,
EM analysis of apoptotic cdc48S565G cells revealed an
expansion of the ER [56], hinting to a defect of Cdc48p-
S565G in one of its ER-related cellular functions, namely
homotypic ER fusion and ubiquitin-dependent degradation of
ER luminal and membrane proteins in ERAD. Recently, we
demonstrated that cells expressing mutated CDC48 (cdc48-
S565G) showed markedly increased levels of polyubiquitinated
proteins in total cell lysates [105]. These polyubiquitinated
proteins co-purified with membranous (e.g., ER-derived
microsomes) but not cytosolic fractions [105]. Since
Cdc48p-S565G showed a decreased activity in degrading a
misfolded ER luminal model substrate compared to wild-type
Cdc48p [106], these data hint to a dysfunction of Cdc48p-
S565G in its role in ERAD (Fig. 2, no. 1, 2). Surprisingly, we
observed a strong accumulation of Cdc48p-S565G, polyubi-
quitinated proteins and a number of ER-associated proteins in
mitochondrial fractions obtained by differential centrifugation
[82,105]. This co-purification of Cdc48p-S565G and poly-
ubiquitinated proteins with mitochondria was very stable,
since it persisted further mitochondrial purification applying
sucrose-gradient centrifugation [105]. We further anlyzed these
Fig. 2. Apoptosis in cdc48S565G yeast. Yeast cells expressing mutated CDC48, harboring a mutation in the D2 domain (cdc48S565G), have a high susceptibility to
undergo apoptosis. Cdc48p-S565G shows decreased activity, especially in ERAD (no. 1). This results in the accumulation of polyubiquitinated proteins at
microsomes, in ER stress and ER expansion (no. 2). Aberrant association of polyubiquitinated microsomes to mitochondria might cause damage of mitochondrial
membranes leading to a crucial mitochondrial impairment (no. 3). Alternatively, CDC48 dysfunction might affect mitochondrial function directly (no. 4), although a
mitochondrial function of Cdc48p is currently unknown. The impaired mitochondria produce a burst of ROS (no. 5), triggering caspase activity that ultimately results
in apoptotic cell death (no. 8). ER-derived ROS may contribute to the mitochondrially produced oxidative stress (no. 6) and may enforce mitochondrial impairment
(no. 7).
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device (ZE-FFE) that separates organelles according to their
surface charges and hydrodynamic properties in a continuous
buffer flow upon an electric field [105,107]. We found that the
majority of mitochondria in apoptotic cdc48S565G cells did not
show an altered deflection in the ZE-FFE separation chamber
compared to CDC48 wild-type and were unaffected by
Cdc48p-S565G and polyubiquitination [105]. In contrast, a
small part of the mitochondria was found to strongly associate
with ER-derived microsomes [105,108]. In apoptotic cdc48-
S565G cells this fraction was markedly increased compared to
CDC48 wild-type and contained drastically increased levels
of Cdc48p-S565G, polyubiquitinated proteins and ER-derived
microsomes [105]. Ultrastructural analysis of yeast cells
revealed that the ER demonstrated an increased spatial
proximity to mitochondrial membranes in cdc48S565G cells
(own unpublished data). These data suggest a crucial link
between ERAD dysfunction upon mutation of CDC48 (cdc48-
S565G) and mitochondria. In this model polyubiquitinated
proteins accumulate in/at the ER. The resulting ER stresstriggers ER expansion. The possible concomitant attachment
to nearby mitochondria may result in the transfer of ER-
associated deleterious processes to mitochondrial membranes
(Fig. 2, no. 3).
First, the stress exerted on mitochondrial membranes may
be of physical nature. An expanding ER might apply forces to
or strengthen the interaction with the mitochondrial reticulum,
resulting in damaged mitochondrial membranes. Second, ER
stress might lead to impairment of the turnover of
mitochondrial membranes affecting membrane integrity.
Phospholipids are synthesized within the ER and are then
transported in a ubiquitin-regulated fashion to mitochondria
to renew the mitochondrial membranes [109–111]. Cdc48p is
involved in ubiquitin-mediated ER membrane fusion processes
[7,112]. Thus, CDC48 mutation might specifically affect
membrane transport from the ER to mitochondria. Third,
ROS produced in the ER under ER stress may damage nearby
mitochondrial membranes. In an ERAD-deficient yeast model,
overexpression of misfolded proteins leads to ER stress and
apoptosis [113]. Here, overload of the ER-resident oxidative
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derived ROS [113]. Since the cdc48S565G strain is character-
ized by dysfunctional ERAD [105,106], this raises the
question whether potential ER-derived ROS in cdc48S565G
cells damage nearby mitochondrial membranes (Fig. 2, no. 6
and 7). In either scenario, damaged mitochondrial mem-
branes could lead to the release of cytochrome c into the
cytosol, to the loss of mitochondrial functionality and to a
drastically increased mitochondrial production of ROS (Fig.
2, no. 5). According to previous results obtained in other
apoptotic yeast strains, accumulation of ROS could mediate
the induction of caspase-like enzymatic activity [102],
resulting in events that initiate DNA fragmentation and apo-
ptotic cell death (Fig. 2, no. 8).
Future studies will have to address the mechanisms of
Cdc48p-S565G-mediated mitochondrial damage (Fig. 2, no. 3,
4). Of special interests are the elucidation of ERAD and ER
stress components that mediate or mimic upon mutation the
specific pro-apoptotic effect of Cdc48p-S565G. In a previous
study, Haynes and colleagues discovered ERV29 as a gene
essential for the elimination of misfolded proteins form the ER
[113]. Challenging ERAD by overexpressing the misfolded
model ERAD substrate CPY⁎ (mutated carboxypeptidase Y) in
an erv29Δ strain resulted in persistent ER stress and in the
subsequent induction of the unfolded protein response that
triggered ER-derived ROS and mitochondria-dependent apop-
totic cell death in yeast [113]. These authors could show that the
unfolded protein response components IRE1 and HAC1 were
critical for the production of ROS and for triggering cell death
[113]. It is tempting to speculate that the ERAD gene ERV29
and the ER stress/unfolded protein response genes IRE1 and
HAC1 may also play a role in mediating the pro-apoptotic
stimulus of Cdc48p-S565G. Beside the evaluation of ERAD
and ER stress genes in apoptosis, the systematic analysis of
different CDC48 mutations (e.g., non-apoptotic alleles vs. pro-
apoptotic cdc48S565G) may further enable a better under-
standing how dysfunction of CDC48-mediated cellular pro-
cesses trigger apoptotic cell death.
3. Cdc48/VCP-mediated apoptosis in other species
3.1. Mammalian cells
A role of mammalian VCP in apoptosis became evident
from a study of Shirogane and colleagues [68]. Applying a
cDNA extraction approach, these authors searched for target
genes that are specifically expressed in stimulated murine
cells expressing the cytoplasmic serine/threonine kinase Pim-
1, a protein involved in gp130/STAT3-mediated cell survival
and cell proliferation [68]. They found VCP to be strongly
induced upon expression of Pim-1 [68]. VCP was assigned to
have anti-apoptotic functions, since overexpression of VCP
was able to partially replace Pim-1 in its role in promoting
cell survival [68]. In contrast, expression of mutant VCP with
critical mutations in the conserved ATP binding sites of both
ATPase domains (D1 and D2; lysine to alanine substitutions:
K251/524A, see Fig. 1) resulted in a drastic decrease in cellproliferation and massive induction of apoptotic cell death, as
evidenced by the emergence of DNA fragmentation [68]. This
mutant VCP strongly inhibited gp130/STAT3-mediated cell
proliferation and suppressed the expression of the anti-
apoptotic protein Bcl-2 [68]. Thus, Pim-1 may induce VCP
expression, in order to mediate gp130/STAT3-mediated cell
proliferation and cell survival [68]. This initial study on the
role of mammalian VCP in apoptosis demonstrated for the
first time that increased levels of wild-type VCP have an anti-
apoptotic effect, whereas expression of mutant VCP triggers
cell death with apoptotic features. Since then several studies
aimed at elucidating the role of VCP activity on cell survival
and cell death.
3.1.1. Mutation and oxidative modification of VCP promote
apoptosis
The pro-apoptotic role of VCP harboring mutations in its
ATPase domains was confirmed in other studies [36,114].
These authors generated a series of VCP mutations, expressed
them in neuronally differentiated PC12 (rat pheochromocy-
toma) cells, and evaluated the cells for morphological
alterations and the induction of cell death [36]. They revealed
that the second ATPase domain of VCP (D2) is critical for
cell survival (see Fig. 1). Deletion of the D2 domain,
mutation of the conserved ATP binding (lysine 524 to alanine,
K524A) or ATPase active site (glutamate 578 to glutamine,
E578Q) of this domain resulted in pro-apoptotic VCP
variants, with the deletion mutant and VCP-K524A showing
the strongest effects [36]. In contrast, expression of critical
mutations in the first ATPase domain (D1) had no severe
effects on cell viability [36]. The ATPase activity of
recombinantly expressed VCP-K524A was strongly reduced
when compared to wild-type VCP [114]. Since the D2
domain of VCP is responsible for the major ATPase activity
[5], the detrimental effect of D2 mutations on cell survival is
very likely due to loss of the ATPase activity of VCP.
Cells expressing ATPase-deficient VCP-K524A are charac-
terized by strong vacuolization followed by cell death
[36,115]. Ultrastructure analysis revealed that the membranes
of the emerging vacuoles bound ribosomes [36]. From the
known roles of VCP in ER-related functions (ER membrane
fusion and ERAD), the authors suggested that this abnormal
vacuoles originated from the ER upon dysfunction of VCP
[36]. Indeed, the cytoplasmic vacuoles could be stained with an
ER marker, and the significantly increased expression of BiP/
GRP78 mRNA and CHOP protein, two ER stress markers,
hinted to the induction of ER stress [114]. Accumulation of
polyubiquitinated proteins in membrane fractions but not in
cytosolic fractions, as well as decreased degradation of the
ERAD substrate mutant CFTR demonstrated dysfunction of the
ATPase-deficient VCP in its role in ERAD [114]. The observed
apoptotic cell death in cells expressing ATPase-deficient VCP-
K524A is thus accompanied with ERAD dysfunction, the
induction of ER stress and abnormal ER expansion [114] (Fig.
3A, no. 1, 2). These data suggest that VCP mutations in the
second ATPase domain (D2) trigger cell death via an ER stress-
mediated apoptotic pathway.
Fig. 3. Role of mammalian VCP during apoptosis. (A) Induction of apoptosis upon loss-of-function of VCP. VCP depletion, mutation or oxidative modifications result
in decreased cellular activity of this protein, causing VCP dysfunction especially in ERAD (no. 1). This causes ER stress and aberrant ER expansion (no. 2) that trigger
caspase activity and apoptotic cell death (no. 6). VCP dysfunction may also cause oxidative stress (no. 3) and/or ER stress may trigger the mitochondrial production of
ROS (no. 4). Oxidative stress may enforce VCP dysfunction due to increased oxidative modification (no. 5). (B) Pro-apoptotic functions of wild-type VCP. Upon
chemically-induced ER stress VCP becomes an essential component of a large ER-associated complex (no. 1) that triggers the processing and activation of the pro-
caspases 9 and 12 (no. 2). The active caspases cause apoptotic cell death (no. 3).
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not of yeast Cdc48p, can be negatively modulated by oxidative
stress [116]. Applying oxidative stress (e.g., via low doses of
hydrogen peroxide) resulted in decreased ATPase activity of
VCP. This effect could be reversed by treatment with reducing
agents, such as DTT [116]. The authors of this study revealed
that the decreased ATPase activity upon oxidative stress was
due to oxidative modification of distinct cysteine residues
within VCP [116]. One of these residues, cysteine 522, a residue
conserved in metazoan organisms but not in protozoans like
yeast, was found to be especially important in the regulation of
the ATPase activity of VCP [116]. Replacement of cysteine 522
with the similar residue threonine, which cannot be oxidized,
resulted in a VCP variant (VCP-C522T) that demonstrated an
oxidative stress-resistant ATPase activity [116]. In contrast,
replacement of cysteine 522 with the residue lysine mimicking
the oxidated state of cysteine (VCP-C522K) resulted in
decreased VCP-ATPase activity, in aberrant ER expansion, in
the induction of ER stress and cell death, highly similar to the
expression of ATPase-deficient VCP-K524A [116]. Therefore,
the decrease in the ATPase activity of endogenous VCP upon
oxidative stress affects the functionality of the ERAD pathwaytriggering ER stress-mediated cell death [116] (Fig. 3A, no. 1, 2,
6). It is thus possible that in mammalian cells an additional level
of regulation occurs, where oxidative stress amplifies ERAD
dysfunction and ER stress through oxidative modification of
VCP (Fig. 3A, no. 5).
3.1.2. VCP depletion may have both pro- and anti-apoptotic
effects
Loss of ATPase activity of VCP through mutation or
oxidative modification results in ERAD dysfunction, ER
stress and apoptotic cell death [36,68,114,116]. Depletion of
VCP should also result in decreased cellular activity of VCP
and should have consequently similar detrimental effects on
cell survival (Fig. 3A). In fact, applying an RNA interference
(RNAi) approach in human HeLa cells, Wojcik and
colleagues demonstrated that depletion of VCP affected
ubiquitin-dependent protein degradation, leading to the
cellular accumulation of polyubiquitinated proteins [117].
The observed dispersed aggregates of polyubiquitinated
proteins upon RNAi of VCP and the inhibition of aggresome
formation, i.e., large centrosomal cellular aggregates, further
hinted to a VCP-related dysfunction of the ubiquitin–
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amounts, a considerable cytoplasmic vacuolization was
found [117], as observed in cells expressing ATPase-deficient
VCP. Analysis of these vacuoles with fluorescence and
electron microscopy confirmed that these vacuoles origin
from an aberrant expansion of the ER [117,118]. As observed
in cells with decreased VCP-ATPase activity, RNAi of VCP
resulted in reduced cell proliferation and triggered apoptotic
cell death [117]. Induction of the pro-apoptotic factor p53 and
cleavage of the caspase substrate PARP was correlated with
the emergence of caspase-3/7 activity [117]. Therefore,
depletion of VCP has highly similar effects on cells like the
expression of ATPase-deficient variants of VCP: ERAD
dysfunction, ER expansion, and ER stress that are causing
or correlated with apoptotic cell death (Fig. 3A). Wojcik and
colleagues observed that a marked number of VCP-depleted
cells demonstrated mitotic abnormalities due to the lack of
mitotic progression beyond pro-metaphase/metaphase [117].
Such an effect on cell cycle progression was not described in
mammalian cells expressing ATPase-deficient VCP [36,114].
Thus, although depletion of VCP applying RNAi and
expression of ATPase-deficient VCP have very similar effects
on cellular function, the loss of VCP activity upon both
methods is not perfectly equivalent. An explanation could be
that the various VCP-related cellular functions, such as ERAD
and cell cycle control, respond differently to VCP depletion
and VCP-ATPase-deficiency.
In a successive study, Wojcik and colleagues system-
atically examined the consequences of VCP depletion
applying a microarray analysis [118]. They identified 27
transcripts to be specifically upregulated upon RNAi of VCP
[118]. Many of these transcripts code for proteins that are
known to be upregulated upon ER stress and to be involved
in the unfolded protein response, such as ATF3 (activation
transcription factor 3) and BiP/GRP78 [118]. Five transcripts
code for proteins participating in apoptosis, such as Harakiri, a
pro-apoptotic protein that binds and inactivates the death-
repressor proteins Bcl-2 and Bcl-XL [118,119]. Several
transcripts code for proteins involved in oxidative stress
response, such as cytosolic flavin reductase [118]. This suggests
a role of oxidative stress during apoptotic cell death upon
VCP depletion. If oxidative stress is a direct result of the
observed ER stress or if it arises from other sources, such as
mitochondria, remains an open question (Fig. 3A, no. 3, 4).
Oxidative stress modulates ATPase activity of VCP and
therewith ERAD functionality and ER stress [116] (Fig. 3A,
no. 5). In this context, it could play an important role in
modulating apoptotic cell death due to VCP dysfunction [116].
Surprisingly, there are also studies that propose a pro-
apoptotic role of functional VCP expressed at physiological
levels [120,121] (Fig. 3B). In a proteomic screen to identify
potential mediators of ER stress-triggered cell death, Rao and
colleagues identified VCP to accumulate in caspase-activating
microsomal extracts upon chemically-induced ER stress
[121]. These authors could show that functional VCP was
necessary for processing of caspase-9 in cell-free microsomal
extracts under these conditions [121]. VCP depletion applyingRNAi prohibited caspase-9 processing and activation and
resulted in a reduction of chemically-induced ER stress-
triggered cell death [121]. Because of the observed increased
binding of VCP to caspase-9 and caspase-12 upon ER stress,
the authors proposed that VCP might be part of a large
protein complex necessary for caspase processing during ER
stress-triggered apoptotic cell death [120,121] (Fig. 3B).
These authors suggested the name “ERaptosome” for this
VCP-containing ER-associated complex following the descrip-
tion of the mitochondria-associated “apoptosome” that is
involved in caspase processing in mitochondria-dependent
apoptotic pathways [120,121]. Therefore, functional VCP may
play a pro-apoptotic role during cell death triggered by
exogenously applied ER stress [120,121].
This idea appears to contradict results where loss-of-function
of VCP via depletion, mutation or oxidative modification
causes ER stress and triggers cell death [36,82,105,114,
117,118] (see Fig. 3A). An explanation may be the fact that
Rao and colleagues did their experiments in cells lacking Apaf-
1 [121], and therefore these cells were unable to perform the
“classical” mitochondria-dependent apoptotic pathway
[121,122]. However, a mitochondrial role during cell death
upon VCP dysfunction, which could compete with the ER-
associated cell death pathway that requires functional VCP, is
currently unknown. Nonetheless, both dysfunctional VCP and
functional VCP are able to cause apoptosis. Consequently, cells
challenged with increased ER stress facilitating the ER-
associated apoptotic pathway requiring functional VCP should
benefit from VCP depletion (Fig. 3B). In contrast, cells not
exposed to ER stress would suffer from ER stress caused by the
VCP depletion itself (see Fig. 3A).
Proteins that misfold and aggregate within the ER, such as
the cystic fibrosis-causing mutant chloride channel CFTR
(cystic fibrosis transmembrane conductance regulator), cause
ER stress [123,124]. In a recent study in mammalian lung cell
lines, ERAD inhibition via VCP depletion (RNAi) prevented
mutant CFTR degradation and promoted its stabilization [123].
In mutant CFTR expressing cells, these authors were unable to
see the induction of apoptosis upon depletion of VCP, and
proposed RNAi of VCP as a therapeutical tool for rescuing
functional mutant CFTR [123]. Relieve of mutant CFTR-
triggered ER stress via VCP depletion possibly overcompen-
sated the ER stress caused by the VCP depletion itself under
these conditions.
3.1.3. Elevated cellular amounts of VCP may play an anti-
apoptotic role
The notion of an anti-apoptotic role of VCP, as originally
described by Shirogane and colleagues [68], was substantiated
by the fact that increased levels of VCP strongly correlate
with poor prognosis and metastasis of various human cancers,
i.e., cells that are characterized by decreased ability to undergo
apoptosis [42–55]. Nuclear factor kappa B (NFκB) is a
transcription factor that upon stimulation translocates into the
nucleus and triggers the expression of genes that promote cell
proliferation and that protect cells against apoptosis [125].
VCP has been proposed to be critically involved in the
Fig. 4. Pro-survival role of elevated amounts of VCP. Increased cellular amounts of VCP protect cells from undergoing apoptosis and promote cell proliferation. VCP
expression is regulated by the transcription factors PBX1 and E47-like factor 2. Elevated VCP levels or VCP phosphorylation by the pro-survival kinase Akt (no. 1)
trigger VCP-dependent dissociation of IκBα, the inhibitor of the pro-survival transcription factor NFκB (no. 2). Activated NFκB translocates into the nucleus inducing
the expression of pro-survival and pro-proliferative genes (no. 3).
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NFκB IκBα [126,127]. Therefore, increased levels of VCP
may result in decreased levels of IκBα and consequently in
hyperactive NFκB signaling promoting cell proliferation (Fig.
4, no. 1–3). In fact, Asai and colleagues identified VCP to be
specifically upregulated in the subline LM8 of the murine
osteosarcoma cell line Dunn [126]. LM8 had a higher
metastatic potential and demonstrated, in contrast to the
control Dunn cell line, a constitutive active expression of
VCP [126]. Dunn cells overexpressing VCP mimicked the
increased metastasis observed in LM8 cells and demonstrated
decreased susceptibility to undergo apoptosis upon treatment
of tumor necrosis factor α (TNFα) [126]. VCP over-
expression was correlated with constantly activated NFκB,
suggesting that high levels of VCP may indeed promote cell
proliferation and cell survival through hyperactive NFκB
signaling [126].
The serine/threonine kinase Akt is another important me-
diator of cell survival and cell proliferation [128]. It pro-
motes cell survival by indirectly activating NFκB signaling
[129]. VCP has been recently shown to be a target of Akt
signaling in neuronal cells and in MCF-7 breast cancer cells
[130–132]. VCP interacted and co-localized with Akt uponAkt activation [130,132]. Three serine residues in VCP were
identified to be phosphorylated by Akt upon stimulation
[130,132] (Fig. 4, no. 1a). Replacement of these serines with
alanines resulted in a VCP triple mutant (S351/745/747A)
that upon expression in breast cancer cells markedly de-
creased the Akt-mediated pro-survival effect of fibroblast
growth factor 2 (FGF2) [132]. Strikingly, this VCP variant
also inhibited the activation of NFκB by FGF2 [132].
Therefore, increased levels of VCP promote cell proliferation
in providing a switch between the pro-survival pathways
mediated by Akt and NFκB (Fig. 4).
Two recent studies dealt with the question which factors
regulate the expression of VCP in cancer cell lines [133,134].
Qiu and colleagues and Zhang and colleagues identified the
pre-B-cell leukemia transcription factor 1 (PBX1) and the
E74-like factor 2, respectively, to bind in MCF7 mammary
carcinoma cell line to the 5′ region of the VCP gene
[133,134]. Both transcription factors induced VCP expression
[133,134] (Fig. 4, no. 1b). Since knock-down of these factors
reduced both VCP levels and cell viability and increased the
susceptibility of the cells to undergo apoptosis, these factors
may play an important role in the regulation of VCP-mediated
cell survival [133,134] (Fig. 4).
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The zebrafish orthologue of Cdc48/VCP was originally
identified to be a major cold-inducible protein in cold-treated
fish [135]. The cellular amount of CDC48 increased during
cold treatment over several days, but decreased markedly
within one day after zebrafish cells (ZE cell line) were kept
again in warm water [135]. Overexpression of CDC48
resulted in increased cell proliferation compared to the
mock-transfected control, as measured by cell growth and
increased DNA synthesis (BrdU assay) [66]. This effect was
much more pronounced with cells kept at cold temperatures
compared to cells grown in warm medium [66]. The observed
increased cell proliferation was correlated with significantly
decreased apoptotic cell death, as evidenced by reduced
numbers of cells showing DNA fragmentation (TUNEL assay)
[66]. Thus, CDC48 is a cold-inducible protein that shows an
anti-apoptotic effect and promotes cell proliferation in
zebrafish cells. The authors also analyzed the effect of
expression of a mutant CDC48 with a tyrosine 805 to alanine
replacement (Y805A) at the C-terminal site of the protein [66]
(see Fig. 1). Expression of this mutant resulted in markedly
decreased cell proliferation and significantly increased apoptotic
cell death [66]. The tyrosine 805 residue is highly conserved and
can also be found in mammalian VCP, in yeast Cdc48p, and in
Xenopus p97/VCP [11,66,136]. This residue is a known
phosphorylation site of mammalian VCP and yeast Cdc48p
[11,136–139]. Specific phosphorylation and dephos-
phorylation of this residue via membrane-bound tyrosine ki-
nases and tyrosine dephosphatases has been implicated in the
regulation of the VCP-dependent assembly of the transitional
ER in mammalian cells (membrane fusion) [136,138,139] and
in the cell cycle dependent nuclear localization of yeast Cdc48p
[11]. However, the role of the phosphorylation of this tyrosine
residue in zebrafish cells remains to be elucidated. Never-
theless, the induction of apoptotic morphology in zebrafish
cells expressing the CDC48 mutant lacking this important
phosphorylation site suggests that dysfunction of Cdc48/VCP
in membrane fusion and cell cycle processes might also
sensitize cells to undergo programmed cell death. It would be
of special interest if homologous mutations in yeast Cdc48p
and mammalian VCP cause similar phenotypes and if the
effects are different from the known apoptosis-triggering
mutations in these species. These mutations locate in the
second ATPase domain of Cdc48/VCP (e.g., cdc48S565G and
VCP-K524A), instead of the very carboxy-terminal site, and
appear to affect predominantly ubiquitin-dependent processes
and not membrane fusion and cell cycle functions of Cdc48/VCP
[36,56,114].
3.3. C. elegans
Using a yeast two-hybrid system to screen for interactors
of CED-4, a central regulator of programmed cell death in
C. elegans, Wu and colleagues identified the Cdc48/VCP ho-
mologue MAC-1 (member of the AAA family that bind CED-4)
as a new potential interactor [69]. The interaction of MAC-1 toCED-4, and also to Apaf-1, the mammalian homologue of
CED-4, was confirmed with immunoprecipitation studies [69].
MAC-1 also interacted with the nematode cell death regulators
CED-3 and CED-9 when co-expressed in mammalian cells
(293Tcells) [69]. It is an essential protein, since depletion of this
protein applying RNAi resulted in animals that arrest mostly in
the second stage of larval development [69]. MAC-1 demon-
strated to have an anti-apoptotic effect. Elevated expression of
MAC-1 in a transgenic strain of C. elegans prevented cells
to undergo programmed cell death [69]. Consistently, MAC-1
prevented CED-3 and CED-4 from causing apoptosis in mam-
malian cells (293T cells) [69]. Therefore, MAC-1 is a negative
regulator of apoptosis in nematodes.
Although MAC-1 is a member of the AAA-ATPase family
and resembles most to yeast Cdc48p and mouse VCP [69],
it remains an open question, whether MAC-1 is a functional
homologue of Cdc48/VCP. Recently, two proteins have been
identified in C. elegans with increased homology to Cdc48/
VCP and with typical Cdc48/VCP functionality, e.g., in ERAD
[40,140–143]. It is currently unknown, whether these Cdc48/
VCP orthologues have similar roles in programmed cell death
like MAC-1.
3.4. Drosophila
In a genetic screen, the Drosophila orthologue of Cdc48/
VCP ter94 has been identified as a dominant suppressor of the
eye degeneration pathway triggered by targeted expression of
human neurotoxic proteins comprising abnormally expanded
polyglutamine stretches (ex-polyQ) [144]. In this Drosophila
model for human polyglutamine disorders, flies harboring a
hypomorphic allele of the ter94 gene beside a normal wild-type
ter94 allele, i.e., flies expressing decreased amounts of ter94
protein, showed a drastically decreased degeneration of the
Drosophila compound eye [144]. Drosophila containing two
copies of the hypomorphic alleles of the ter94 gene, however,
showed zygotic embryonic lethality, underlining the vital role of
ter94 in Drosophila [144]. Comparison of different hetero-
zygous loss-of-function mutations of ter94 demonstrated that
increased loss-of-function of ter94 strongly correlated with
decreased eye degeneration [144]. From these data, it was pro-
posed that ter94 might be a positive effector in the polyQ-
induced cell death pathway. Consistent with this idea, expres-
sion of ter94 was upregulated in ex-polyQ-expressing cells
before these cells started to die, and co-expression of ex-polyQ
and ter94 severely enhanced the observed eye degeneration
[144]. The pro-degeneration effect of ter94 was independent
of the expression of ex-polyQ, because overexpression of
ter94 in Drosophila eyes caused dose-dependently consider-
able degeneration of the eye due to massively increased apo-
ptotic cell death, as evidenced by the increased numbers of
cells showing DNA fragmentation [144]. Genetic analysis
proved that ter94 did not act downstream of neither the known
three major apoptosis-inducing genes in Drosophila, namely
grim, reaper, and hid nor the nematode ced4 and human p53
pro-apoptotic genes [144]. Therefore, ter94 is a cell death
effector by itself. From these data, the authors of this study
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pro-apoptotic effector in ex-polyQ-triggered cell death, and
that decreasing the amount of VCP might be beneficial for cell
survival [144].
However, in no other species tested so far do increased
levels of Cdc48/VCP cause apoptotic cell death. In contrast,
mammalian VCP has been assigned to have an anti-apoptotic
role in several studies [68,126]. Decreased incidences of cell
death and increased cell proliferation were also observed in
zebrafish overexpressing the zebrafish orthologue CDC48
[66]. However, there is evidence that mammalian VCP may
also be a direct mediator of ER stress-triggered apoptotic cell
death [120,121] (see Section 3.1.2 and Fig. 3B). Here, VCP is
necessary for caspase processing in ER-associated apoptotic
cell death [120,121]. Thus, there might be distinct apoptotic
pathways that need functional Cdc48/VCP for being effective
in killing the cells. In a context that favors such a pro-
apoptotic role of Cdc48/VCP increased levels of this protein
could be harmful for cell survival, as observed in Drosophila
overexpressing ter94/VCP in the compound eye. A cellular
context with such a pro-apoptotic role of Cdc48/VCP could be
found in post-mitotic cells [144]. Indeed, ter94 and ex-polyQ
were overexpressed in highly differentiated non-dividing cells
(e.g., photoreceptor neurons) and triggered cell death in these
very specialized cells. Many human neurodegenerative
diseases are characterized by the loss of such specialized
post-mitotic cells [144]. In contrast, the anti-apoptotic
functions of Cdc48/VCP were described in less-specialized
dividing cells, such as immortalized cancer cells [68,126].
3.5. Trypanosomes
TbVCP is the orthologue of Cdc48/VCP in African trypa-
nosomes, protozoan parasites causative for sleeping sickness
in humans [67]. Lamb and colleagues demonstrated that
TbVCP is essential for trypanosome viability. Only one of the
two homologous copies of the TbVCP gene could be
disrupted without decreasing cell survival [67]. Constitutive
overexpression of TbVCP with critical mutations in the D2
domain responsible for the major ATPase activity of this
protein (see Fig. 1) failed due to the lethality of these TbVCP
variants [67]. Consistent with the results observed in other
species, regulated overexpression of these variants resulted in
growth arrest (at all stages of the cell cycle) and cell death
one day after triggering expression [67]. Cells expressing
TbVCP mutants showed severe and characteristic morpholo-
gical alterations [67]. Double mutants of TbVCP affecting
both the D1 and the D2 domain of TbVCP resulted in a
distinct phenotype in cells expressing these mutants [67].
Thus, in contrast to mammalian VCP, the D1 domain of
TbVCP may be involved in the modulation of cell death in
trypanosomes. TbVCP complemented and functionally
replaced yeast Cdc48p despite of the great phylogenetic
distance between trypanosomes and yeast [67]. Therefore, it
might be of high interest if the morphological description of
cell death in trypanosomes is based on similar mechanistic
processes as observed in yeast.4. Triple role of Cdc48/VCP in apoptosis
Cdc48/VCP is an essential protein, since knock-out of
VCP results in early embryonic lethality or non-viable cells in
numerous species, such as yeast [3,56,70], mammalian cells
[145], Drosophila [144], and trypanosomes [67]. Loss-of-
ATPase-activity of Cdc48/VCP has severe effects on cell
survival and causes apoptotic cell death in all species tested
so far, namely yeast [56], mammalian cells [68], and
trypanosomes [67]. Therefore, the ATPase activity of
Cdc48/VCP is, like the whole protein, essential for cell
survival. The major ATPase activity of Cdc48/VCP is located
in the second ATPase domain (D2) of this protein [5,8] (see
Fig. 1). Critical mutations in this domain drastically affect the
ATPase activity of Cdc48/VCP [8,114]. Cells expressing
ATPase-deficient Cdc48/VCP demonstrate predominantly
ERAD defects accompanied by ER stress and apoptotic cell
death:
(i) Yeast cells expressing mutated CDC48 with a serine to
glycine replacement within the D2 domain (cdc48S565G)
demonstrate marked deficits in ERAD causing ER stress
and ER expansion [56,105] (Fig. 2, no. 1, 2). The
detrimental settings within the ER upon CDC48 mutation
might affect mitochondria via increased association of ER-
derived microsomes to mitochondrial membranes [82,105]
(Fig. 2, no. 3). Nonetheless, a direct effect of CDC48
mutation on mitochondrial function cannot be excluded
(Fig. 2, no. 4). Consequently damaged mitochondria
generate a burst of oxidative stress and trigger apoptotic
cell death [82] (Fig. 2, no. 5, 8). Overload of the ER-
resident oxidative protein folding machinery may con-
tribute to the oxidative stress and may enforce mitochon-
drial impairment (Fig. 2, no. 6, 7).
(ii) Mammalian cells expressing VCP with critical mutations
within the D2 domain, especially VCP-K524A, also show
pronounced ERAD impairment causing ER stress and the
induction of the unfolded protein response [36,114] (Fig.
3A, no. 1a, 2). Cells consequently die in an apoptotic
fashion after the emergence of large cytoplasmic vacuoles
that originate from abnormally expanded ER [36,114] (Fig.
3A, no. 2, 6). These astonishingly similar phenotypes
observed in yeast and mammalian cells suggest that
mitochondria and oxidative stress may also play a role in
apoptotic cell death in mammalian cells expressing ATPase-
deficient VCP (Fig. 3A, no. 3, 4). In mammalian cells but not
in yeast, endogenous VCP can be reversibly oxidized leading
to a decrease in its ATPase activity, resulting in ER stress
[116] (Fig. 3A, no. 1b). Regulation of VCP-ATPase activity
might play an important role in modulating oxidative stress
and ER stress. Therefore, in mammalian species, oxidative
stress may amplify ERAD dysfunction and ER stress in a
positive feedback loop (Fig. 3A, no. 5).
Depletion of VCP in mammalian cells results in dysfunc-
tion of VCP-dependent degradation of proteins [117,118]
(Fig. 3A, no. 1c). Consistent with the results observed in cells
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ER stress, unfolded protein response and apoptotic cell death
[117,118] (Fig. 3A, no. 2, 6). VCP depletion induces the
expression of proteins involved in oxidative stress [118],
underlining a potential role of oxidative stress and
mitochondria during apoptosis upon VCP dysfunction (Fig.
3A, no. 3, 4).
In some cases, depletion of VCP prevents the cells from
undergoing ER-associated apoptotic cell death triggered by
sustained ER stress [121] (Fig. 3B, no. 1-3). Functional VCP
has been suggested to be an effector in such cell death
scenarios [120,121]. It plays an essential role in the
processing and activation of caspases, resulting in cell
death (Fig. 3B, no. 2, 3). The cellular context may determine
if depletion of VCP is beneficial or detrimental for cell
survival.
Elevated cellular levels of Cdc48/VCP lead to increased
cell proliferation in mammalian cells [68,126], correlated with
increased incidence of cancer and metastasis [42–55], and to
increased cell proliferation in zebrafish [66]. In contrast,
significantly (but not moderately) increased levels of ter94,
the Drosophila orthologue of Cdc48/VCP, trigger apoptotic
cell death in highly specialized and differentiated cells of the
compound eye of the flies, suggesting a pro-apoptotic role of
this protein at least under this very specialized context [144].
The anti-apoptotic role of elevated levels of mammalian VCP
may be a result of the VCP-dependent activation of the pro-
survival NFκB signaling [126,127] that is further regulated by
phosphorylation of specific serine residues of VCP by the
anti-apoptotic kinase Akt [132] (Fig. 4).
In summary, Cdc48/VCP affects apoptotic and anti-
apoptotic cellular processes in at least three different ways:
(i) Loss of Cdc48/VCP-ATPase activity due to mutation,
oxidative modification or Cdc48/VCP depletion affects
predominantly the Cdc48/VCP-dependent ERAD path-
way, triggering ER stress, unfolded protein response,
apoptotic cell death with possible pivotal roles of
mitochondria and oxidative stress (see Figs. 2, 3A).
This seems to be the predominant Cdc48/VCP-dependent
pathway and it is highly conserved from yeast to
mammalian cells.
(ii) Functional Cdc48/VCP is an essential pro-cell death
effector molecule in specialized apoptotic cell death
pathways, as observed in mammalian cells, in which
cells die via an ER stress-triggered ER-associated apoptotic
pathway (see Fig. 3B), and in specialized eye cells in
Drosophila.
(iii) At elevated cellular levels, Cdc48/VCP can also increase
the protection of cells against cellular stressors and
apoptotic stimuli by stimulating the pro-survival NFκB
pathway (see Fig. 4).
Cdc48/VCP therefore plays variant roles in cell survival
and cell death that may manifest differently in various cell
types, under different environmental conditions or in
individual species. This complexity in the effect of Cdc48/VCP on cell survival and cell death may be a mirror of its
different cellular functions, indicating an integrative position
of Cdc48/VCP in the adaptation to intracellular stress
responses.
5. Cdc48/VCP-mediated apoptosis: implications to human
disease
5.1. IBMPFD
Point mutations in the VCP gene have been described as
causative for ‘inclusion body myopathy associated with
Paget's disease of bone and frontotemporal dementia’
(IBMPFD), a rare human multisystem disorder [26–35].
IBMPFD is characterized by adult-onset of proximal and
distal muscle weakness, early onset of Paget's disease of
bone, a metabolic bone disease that is characterized by
overactive osteoclasts containing nuclear inclusions [146], and
premature frontotemporal dementia [147,148]. Affected indi-
viduals suffer at least from one of these features. IBMPFD is
inherited in an autosomal dominant fashion. In IBMPFD VCP
was found in large or small rounded protein aggregates in
affected scattered muscle fibers [34] or in neuronal nuclear
inclusions comprising aggregated ubiquitinated proteins [35].
Therefore, it has been proposed that upon mutation dys-
function of VCP in its role in ubiquitin-dependent protein
quality control might be causative for the disorder.
Most known mutations of VCP, comprising the most pre-
valent mutations, lie within the N-terminal domain but not in
the conserved AAA-ATPase domains [31,33,34] (see Fig. 1).
Recent data demonstrate that they do interfere neither with
hexamerization of VCP nor with its ATPase activity [149].
Nonetheless, dysfunction of the ubiquitin–proteasome system
and more specifically of ERAD has been observed in cells
expressing these mutants, although the reasons for this dys-
function remain elusive [149]. The accumulation of poly-
ubiquitinated aggregates and abnormally altered ER structure
in these cells [149] suggest that ER stress is induced with
potentially detrimental effects on cell survival (see Fig. 3A),
as observed in cells with ATPase-deficient Cdc48/VCP, e.g.,
yeast cells expressing mutated CDC48 (cdc48S565G)
[56,82,105]. Increased cell loss due to the induction of
apoptotic cell death may thus be one factor that results in the
manifestation of the IBMPFD disease. However, since the
IBMPFD-causing mutations do not affect the critical second
ATPase domain (D2), additional factors, such as environ-
mental factors, ageing, and genetic determinants may be
needed for triggering apoptotic cell death. For instance,
apolipoprotein E (APOE), a known genetic modifier of
Alzheimer's disease, was recently identified to correlate with
altered emergence of frontotemporal dementia in people
suffering from IBMPFD [150]. A systematic analysis using
various apoptotic cell models, such as yeast and mammalian
cells, and the recently published transgenic mice expressing
IBMPFD-causing VCP variants [151] may help to elucidate
more critical factors and their roles during cell death in
IBMPFD.
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IBMPFD is a human disorder characterized by aberrant
protein depositions. However, formation of protein aggre-
gates, intranuclear or cytoplasmic inclusion bodies and
extracellular plaques is a hallmark of many human degen-
erative disorders, especially in the pathogenesis of common
neurodegenerative disorders such as Alzheimer's, Parkinson's,
and Huntington's diseases [152–154]. Wild-type VCP co-
localizes in situ with abnormal cellular protein aggregates and
inclusions in motor neuron disease with dementia, in
amyotrophic lateral sclerosis, in Creutzfeldt–Jacob, Alzhei-
mer's, Parkinson's, Huntington's and Machado–Joseph dis-
eases [36–38]. From these data, VCP has been proposed to be
a sensor protein for aggregated proteins associated with
human degenerative disorders [36,37,39].
Huntington's and Machado–Joseph diseases both belong
to a class of inherited neurodegenerative disorders character-
ized by the expansion of polyglutamine stretches (ex-polyQ)
in those proteins responsible for each disorder. These
expansions frequently lead to aggregation of these proteins
[155]. In this context, VCP has been identified as an ex-
polyQ interacting protein in vitro and in vivo [36]. In C.
elegans the two identified VCP homologues modulate the
aggregation of ex-polyQ proteins [40]. In mammalian cells
VCP plays a dual role and is involved in both the clearance
and formation of the abnormal protein aggregates caused by
ex-polyQ proteins, and other aggregation-prone proteins
[39,41].
The role of VCP during (apoptotic) neuronal cell loss
underlining human polyglutamine disorders and other diseases
characterized by abnormal protein aggregates remains elusive.
A genetic screening of a Drosophila model for human poly-
glutamine diseases demonstrated the Drosophila homologue
of VCP (ter94) as a pro-death effector during apoptotic cell
death trigged by ex-polyQ proteins [144]. Loss-of-function of
ter94 prevented ex-polyQ-caused cell death, whereas over-
expression of ter94 enhanced the observed degeneration
[144]. This single study suggests that the pro-apoptotic role of
VCP might play a pivotal role during progression of
polyglutamine disorders.
In contrast, accumulation of detrimental protein aggregates
might result in VCP dysfunction [36,114] (see Fig. 3A). This
may mimic a loss-of-function of VCP, eventually causing ER
stress, unfolded protein response, aberrant ER expansion and
apoptotic cell death [36,114, 117,118]. Indeed, VCP activity
has been shown to be negatively regulated by oxidative
modifications [116], and oxidative stress is highly prevalent
in protein deposition disorders [156]. This strongly suggests
that loss-of-function of VCP may facilitate apoptotic cell
death in these diseases. Therefore, apoptosis triggered by
Cdc48/VCP depletion and Cdc48/VCP mutations may be an
excellent model for the evaluation of cellular mechanisms
underlying cell loss observed during pathogenesis of
degenerative disorders characterized by aberrant protein
depositions. Common features within many of these diseases
are impairment of the ubiquitin-dependent protein degrada-tion, ER stress, oxidative stress and a pathological involve-
ment of mitochondria [152–154,156,157]. All these features
were critically linked in apoptotic yeast cells expressing
mutated CDC48 (cdc48S565G) [56,71,82,105]. Therefore, a
deeper analysis of apoptosis in this yeast model system in
comparison to data obtained from mammalian model systems
may give invaluable insights in the progression of these human
degenerative disorders.
5.3. Cancer
Whereas at endogenous levels VCP is involved in human
degenerative disorders, such as IBMPFD and protein deposi-
tion disorders, elevated levels of VCP have been linked to the
promotion of cancer and increased incidence of metastasis
[42–55]. In certain types of cancer tissues, e.g., colorectal
carcinomas, pancreatic endocrine neoplasms, and follicular
thyroid cancer, the expression level of VCP is markedly
elevated and has been shown to associate with poor
prognosis, proposing VCP expression levels as a useful
marker for the progression of these cancers [42–55].
VCP increases the protection of cells against apoptotic
stimuli through activation of the NFκB signaling pathway
[126,127] (see Fig. 4). Specific transcription factors regulate
VCP expression and therewith NFκB-mediated cell survival
[133,134]. The pro-survival Akt signaling pathway promotes
the role of VCP in this process [132] (see Fig. 4). Targeted
depletion of VCP in these cells might sensitize the cells to
undergo apoptotic cell death due to cellular stress caused by
VCP dysfunction and may interfere with aberrant cell
proliferation and metastasis.
6. Conclusions
Cdc48/VCP is a highly conserved member of the AAA-
ATPase family, involved in various cellular processes [20–
25]. Corresponding to its diverse cellular functions, it plays a
role in different pathophysiological processes. Increased
amounts of VCP are correlated with metastasis and cancer
[42–55]. Upon mutation VCP causes IBMPFD disease [26–
35], whereas wild-type VCP binds to aberrant protein
aggregates characteristic for numerous human degenerative
disorders and has been proposed to mediate cell loss in these
diseases [36–38]. Applying different model organisms from
yeast to mammalian cells, first insights in Cdc48/VCP-
mediated apoptotic processes were obtained. In a yeast model,
mutation of CDC48 results in ERAD dysfunction, ER
expansion and ER stress that is possibly propagated to
mitochondria, causing these organelles to promote oxidative
stress-dependent apoptotic cell death [5,7,56,71,82,105]. Ac-
cordingly, similar mutations in mammalian VCP, as well as
depletion of VCP, show very comparable results [36,68,114,
117,118]. However, a critical role of mitochondria in these
cases has not yet been evaluated. This VCP-mediated
apoptotic scenario may be most relevant for cell loss in
IBMPFD disease and protein deposition disorders. Beside the
induction of apoptosis via loss-of-function of Cdc48/VCP
1431R.J. Braun, H. Zischka / Biochimica et Biophysica Acta 1783 (2008) 1418–1435upon depletion or mutation, functional Cdc48/VCP plays an
additional pro-apoptotic role [120,121,144]. This may be
important for specialized cells that are challenged by
exogenously applied ER stress [120–122]. VCP also protects
cells against apoptotic insults via activation of the NFκB
signaling pathway [126,132]. This could be relevant for VCP-
mediated promotion of metastasis and cancer [126,132].
Therefore, Cdc48/VCP-mediated apoptotic processes are com-
plex, since Cdc48/VCP plays a triple role: (i) induction of
apoptosis upon loss-of-function of the protein, (ii) pro-apoptotic
effector role of endogenous protein, and (iii) anti-apoptotic role
of VCP at elevated protein levels. Elucidation of the interplay of
these three roles of Cdc48/VCP in cell death and cell survival
and the relevance of the individual pathways for human
disorders remains an elaborate task for the future.
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